developed a novel FLT3 gilteritinib-based degrader, CRBN(FLT3)-8 (Figure 58), which effectively degraded FLT3-ITD – a internal tandem duplication mutation in the FLT3 gene - and inhibited the proliferation of FLT3-ITD mutant AML cells more effectively than gilteritinib. This evidence concerns the gene FLT3 and acute myeloid leukemia.